Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7510.09 | 0.6726 | 0.3927 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7510.09 | 0.0013 | -0.9954 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7510.09 | 0.0005 | -0.9982 | 1.0960 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7511.091 | 0.9637 | 0.9339 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7511.091 | 0.9404 | 0.8913 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7511.091 | 0.9367 | 0.8845 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7511.091 | 0.9930 | 0.9873 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7511.091 | 1.0562 | 1.1021 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7511.091 | 0.8867 | 0.7928 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7511.091 | 0.6709 | 0.3912 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7511.091 | 0.0055 | -0.9825 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7511.091 | 0.0010 | -0.9964 | 1.0995 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7512.091 | 0.9906 | 0.9786 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7512.091 | 1.0911 | 1.2080 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7512.091 | 0.9866 | 0.9697 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7512.091 | 1.0030 | 1.0067 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7512.091 | 1.0441 | 1.1003 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7512.091 | 1.0189 | 1.0429 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7512.091 | 0.7888 | 0.5282 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7512.091 | 0.0152 | -0.9826 | 0.8817 | |
| MDA-MB-415 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7512.091 | 0.0054 | -0.9947 | 0.8817 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7515.092 | 0.9227 | 0.8706 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7515.092 | 0.8784 | 0.7956 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7515.092 | 0.8818 | 0.8013 | 1.2024 | |
| MDA-MB-453 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7515.092 | 0.9382 | 0.8967 | 1.2024 |